NEW YORK, June 23, 2021 /CNW/ — MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Maurizio Fava, a world-leading expert in psychiatry and psychiatric clinical trials from Massachusetts General Hospital and the Harvard Medical School to the Company’s Scientific Advisory Board. Dr.


Previous articleCOMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
Next articleBook Review: Alexander Shulgin’s The Nature of Drugs